Catecholaminergic polymorphic ventricular tachycardia

Nian Liu, Barbara Colombi, Emilia V. Raytcheva-Buono, Raffaella Bloise, Silvia G. Priori

Research output: Contribution to journalArticlepeer-review


Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a highly lethal form of inherited arrhythmogenic disease characterized by adrenergically mediated polymorphic ventricular tachycardia. The mutations in cardiac ryanodine receptor and calsequestrin genes are responsible for the autosomal dominant and recessive variants of CPVT, respectively. The clinical presentation encompasses exercise- or emotion-induced syncopal events and a distinctive pattern of reproducible, stress-related, bidirectional ventricular tachycardia in the absence of both structural heart disease and a prolonged QT interval. The mortality rate in untreated individuals is 30-50% by age 40. Clinical evaluation by exercise stress testing and holter monitoring and genetic screening can facilitate early diagnosis. β-adrenergic blockers are the most effective pharmacological treatment in controlling arrhythmias in CPVT patients, yet about 30% of patients still experience cardiac arrhythmias and eventually require an implantable cardioverter defibrillator.

Original languageEnglish
Pages (from-to)212-217
Number of pages6
Issue number3
Publication statusPublished - Mar 2007


  • Catecholaminergic polymorphic ventricular tachycardia
  • Genetics
  • Sudden death
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Catecholaminergic polymorphic ventricular tachycardia'. Together they form a unique fingerprint.

Cite this